dyslipoproteinemia

dyslipoproteinemia

 [dis-lip″o-pro″tēn-e´me-ah]
the presence of abnormal concentrations of lipoproteins, or of abnormal lipoproteins, in the blood. See also hyperlipoproteinemia and hypolipoproteinemia.

dyslipoproteinemia

/dys·lipo·pro·tein·emia/ (-lip″o-pro″te-ne´me-ah) the presence of abnormal concentrations of lipoproteins or abnormal lipoproteins in the blood.

dyslipoproteinemia

an abnormal distribution of lipoproteins in the blood.
References in periodicals archive ?
Plasma lipids and lipoprotein reference values, and the prevalence of dyslipoproteinemia in Canadian adults.
This edition has new and updated coverage of the chemical basis for analyte assays and common interferences, lipids and dyslipoproteinemia, markers in the blood for cardiac injury evaluation and related stroke disorders, among other additions.
Enhanced oxidative stress and dyslipoproteinemia have been proposed as significant factors contributing to the accelerated development of macrovascular complications in diabetes," Dr.
An evaluation of the marmoset Callithrix jacchus (sagui) as an experimental model for the dyslipoproteinemia of human Schistosomiasis mansoni.
Dwyer and Blizzard (1996), collected data on variables associated with dyslipoproteinemia, hypertension, BMI and skinfold thickness in a group (n = 1834) of 9 and 15 year old children.
It has been designed to measure the prevalence of risk factors including dyslipoproteinemia, hyperglycemia, obesity, smoking, and hypertension.
Patent Number 6,673,780, entitled "Sulfoxide and Bis-sulfoxide Compounds and Compositions for Cholesterol Management and Related Uses," covers novel chemical compounds, pharmaceutical compositions comprising the compounds and methods for their use in the treatment of a variety of diseases, such as cardiovascular diseases, dyslipidemia, dyslipoproteinemia and hypertension, and was invented by Esperion scientists.
The first comprehensive classification of dyslipoproteinemia, formulated in the mid 1960s and adopted by the World Health Organization (WHO), described hyperlipoproteinemia as plasma phenotypes.
Hypertriglyceridemia, being associated with hepatic steatosis and oversecretion of large triglyceride-rich VLDL, is central to the pathophysiology of dyslipoproteinemia in type 2 diabetes (7).
Patent Number 6,506,799, titled "Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds," covers methods for the use of certain small molecules to treat a variety of cardiovascular diseases and was invented by Esperion scientists.